Healthcare / Pharmaceutical RetailersNasdaqCM
$0.40
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-14.3M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$16M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-59.2%
↓Gross Margin
76.8%
↑Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
-6.4%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $431609.0 · net income $-41.5M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $431609.00 | $431609.00 | $136643.00 | $1.4M | $10.3M | $9.9M | $17.1M | $7.4M | $3.8M | $2.9M | $2.5M | $2.9M | $1.5M | $955881.00 |
| Net Income | $-41.5M | $-41.5M | $9.1M | $-17.8M | $-3.5M | $-5.3M | $-2.5M | $-284428.00 | $9038.00 | $288983.00 | $-2.8M | $-1.1M | $-2.0M | $-2.1M |
| EBITDA | $-42.1M | $-42.1M | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -2.70 | -2.70 | 2.48 | -23.35 | -6.13 | -0.65 | — | -0.05 | 0.00 | 0.01 | -0.09 | -0.04 | -0.07 | -0.15 |
| Gross Margin | 76.8% | 76.8% | 4.4% | 3.6% | 53.8% | 48.0% | 33.3% | 65.5% | 88.3% | 100.0% | 100.0% | 93.5% | 70.6% | 1.2% |
| Operating Margin | -9867.9% | -9867.9% | -10758.7% | -322.4% | -28.4% | -53.5% | -14.6% | 1.7% | -2.3% | 13.5% | -40.6% | -4.7% | -95.7% | -218.0% |
| Net Margin | -9618.0% | -9618.0% | 6634.7% | -1308.3% | -33.9% | -53.8% | -14.8% | -3.8% | 0.2% | 9.9% | -111.2% | -38.4% | -134.5% | -218.8% |
| Balance Sheet | ||||||||||||||
| Debt/Equity | — | — | 0.04 | — | — | — | — | 0.05 | 0.62 | -2.14 | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | — | — | $-14.3M | — | — | $-2.6M | $-2.3M | — | — | — | — | — | — | $-855568.00 |
| Returns | ||||||||||||||
| ROE | -59.2% | -59.2% | 11.5% | -3290.0% | -455.0% | -141.0% | -29.2% | -6.9% | 1.1% | -92.6% | 240.4% | -418.4% | -301.0% | -1598.0% |
| Growth & Yield | ||||||||||||||
| Revenue Growth | 215.9% | 215.9% | -90.0% | -86.7% | 3.6% | -42.2% | 130.3% | 94.1% | 30.7% | 18.1% | -14.8% | 94.7% | 56.5% | — |
| EPS Growth | -208.9% | -208.9% | 110.6% | -280.9% | -843.1% | — | — | — | -100.0% | 111.1% | -125.0% | 42.9% | 53.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.